Drug Approval | March 27, 2025
European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
